CareDx (NASDAQ: CDNA) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its peers? We will compare CareDx to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, earnings, dividends and analyst recommendations.
Earnings & Valuation
This table compares CareDx and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|CareDx||$48.32 million||-$55.46 million||-11.26|
|CareDx Competitors||$1.13 billion||$76.65 million||204.97|
This is a breakdown of recent ratings and recommmendations for CareDx and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CareDx presently has a consensus price target of $8.88, suggesting a potential upside of 2.36%. As a group, “Medical laboratories” companies have a potential upside of 17.84%. Given CareDx’s peers higher possible upside, analysts clearly believe CareDx has less favorable growth aspects than its peers.
Risk & Volatility
CareDx has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, CareDx’s peers have a beta of 1.23, indicating that their average share price is 23% more volatile than the S&P 500.
This table compares CareDx and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
51.5% of CareDx shares are held by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are held by institutional investors. 5.4% of CareDx shares are held by company insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
CareDx peers beat CareDx on 7 of the 12 factors compared.
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.